What is Thymogen?

A dipeptide (Glu-Trp, also called oglufanide) investigated for effects on immune signaling; not the same molecule as thymosin alpha-1.

Thymogen in the library · Bioregulator Peptides · Human Trials · What are peptides?

0 registered trials · 9 indexed papers · 49 human / 40 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Thymogen is described as a short peptide made from glutamic acid and tryptophan, commonly written Glu-Trp, that has been investigated for effects on immune signaling. Chemical references also call it oglufanide; the National Cancer Institute is described as listing Thymogen and IM862 as names associated with oglufanide disodium, the salt form studied clinically.

It is described as not the same molecule as thymosin alpha-1; the word “immune” does not make their evidence interchangeable. Research spans cells, animals and clinical studies in specific populations and includes a negative trial that belongs in the discussion.

Peer-reviewed studies (9)

PaperAuthorsJournalYearType
[Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity]Smirnov VS et al.Advances in gerontology = Uspekhi gerontologii2011Randomized Controlled Trial
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesMao S et al.The Prostate2007Randomized Controlled Trial
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study TeamNoy A et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2005Randomized Controlled Trial
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaDeplanque G et al.British journal of cancer2004Clinical Trial, Phase II
[Applications of immunomodulators in complex of treatment of the soft tissue purulent wounds]Potiĭ VVKlinichna khirurhiia2000Clinical Trial
Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcomaTulpule A et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2000Randomized Controlled Trial
[The effect of thymogen on the state of immunity in destructive pulmonary tuberculosis]Medus AI et al.Voenno-meditsinskii zhurnal1999Clinical Trial
[Changes of immune and non-specific reactivity in patients with chronic suppurative obstructive bronchitis in comprehensive treatment with thymogen]Litvinova NV et al.Problemy tuberkuleza1994Controlled Clinical Trial
[Thymogen in the complex treatment of inflammatory diseases of the female genital system]Tsvelev IuV et al.Akusherstvo i ginekologiia1992Clinical Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Thymogen?

A dipeptide (Glu-Trp, also called oglufanide) investigated for effects on immune signaling; not the same molecule as thymosin alpha-1.

How many registered human trials study Thymogen?

The PeptideWhiz trial index lists 0 registered trials for Thymogen.

How much published research exists on Thymogen?

The PeptideWhiz paper index links 9 PubMed papers to Thymogen; by study type, 49 human and 40 animal studies.

Which conditions is Thymogen researched for?

Skin, hair loss, wounds & mast-cell/histamine reactivity.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).